<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793348</url>
  </required_header>
  <id_info>
    <org_study_id>AIS 700-00052</org_study_id>
    <nct_id>NCT03793348</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles</brief_title>
  <official_title>A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytrellis Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytrellis Biosystems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study evaluating the efficacy of a micro coring device for the treatment of moderate to
      severe check wrinkles
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 35 subjects who meet the inclusion/exclusion criteria will be treated. All subjects
      will be monitored for a period of 90 days post treatment.

      Study results will be assessed with the following:

        -  Lemperle Scale

        -  Investigator GAIS Scale

        -  Subject Satisfaction Scale
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Anticipated">August 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess level of wrinkle improvement using the Lemperle Wrinkle Severity Scale</measure>
    <time_frame>90 day post treatment</time_frame>
    <description>A mean change of 1 point or greater reduction in cheek wrinkle severity at 90 days post treatment using the Lemperle Wrinkle Severity Scale, as assessed by (3) blinded Independent Reviewers Lemperle Scale:
No wrinkles =0 Just perceptible wrinkles =1 Shallow wrinkles=2 Moderately deep wrinkles=3 Deep wrinkles, well-defined edges =4 Very deep wrinkles, redundant fold=5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess aesthetic improvement using Global Aesthetic Improvement Scale</measure>
    <time_frame>90 day post treatment</time_frame>
    <description>Overall aesthetic improvement level per Principal Investigator at 90 days compared to baseline on the Global Aesthetic Improvement Scale.
Very Much Improved (Optimal cosmetic result)=3 Much Improved (Marked improvement from the initial condition, but not completely optimal)=2 No Change (The appearance is essentially the same as baseline)=0 Worse (The appearance is worse than the original condition)= -1 Much Worse (Marked worsening in appearance from the initial condition)= - 2 Very Much Worse (Obvious worsening in appearance from the initial condition)=- 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess aesthetic improvement using Subject Satisfaction Scale</measure>
    <time_frame>90 day post treatment</time_frame>
    <description>Satisfaction with the aesthetic appearance of the treatment area per Subject Satisfaction Scale compared to baseline.
Extremely dissatisfied=0 Somewhat dissatisfied=1 Slightly dissatisfied=2 Neither satisfied or dissatisfied=3 Slightly satisfied=4 Somewhat satisfied=5 Extremely satisfied=6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess aesthetic improvement in wrinkles using OCT images (optional)</measure>
    <time_frame>Baseline to Day 90 post treatment</time_frame>
    <description>Assessment of improvement using OCT images with Vista software to determine wrinkle depth reduction, comparing pre-treatment depth to post treatment depth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess efficacy results using Canfield Software,, by comparing the changes in wrinkles at baseline and 90 days post treatment.</measure>
    <time_frame>Baseline to Day 90 post treatment</time_frame>
    <description>Validated Canfield software comparing baseline wrinkles to day 90 follow up wrinkles via automated photo analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety profile by recording of adverse events</measure>
    <time_frame>Adverse events will be recorded immediately treatment, Day 1, Day 7, Day 30, Day 60 and Day 90 post treatment. Ad hoc assessment can occur upon subject report of AE.</time_frame>
    <description>The incidence and severity of systemic and local adverse events will be recorded by the PI at all visits and a 14 day diary completed by each subject will also be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety profile by reviewing completed 14 day subject diary for potential side effects.</measure>
    <time_frame>For 14 days post treatment</time_frame>
    <description>14 day diary completed by each subject will record potential side effects, level of severity (mild = 1; moderate = 2; severe = 3), and end date of the potential side effects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Wrinkle</condition>
  <arm_group>
    <arm_group_label>Micro-exisional skin removal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MCD</intervention_name>
    <description>Micro coring skin removal with automated coring device</description>
    <arm_group_label>Micro-exisional skin removal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 40-70 years of age

          -  Fitzpatrick Skin Type I to IV as judged by the Investigator

          -  Cheek areas are at least a score of 3 using the Lemperle Wrinkle Assessment Scale as
             judged by the Investigator

          -  Able to provide written informed consent, understand and willing to comply with all
             study related procedures and follow-up visits.

        Exclusion Criteria:

          -  Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma,
             vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be
             treated

          -  History of keloid formation or hypertrophic scarring

          -  History of trauma or surgery to the treatment areas in the past 6 months

          -  Scar present in the areas to be treated

          -  Silicone injections in the areas to be treated

          -  Injection of dermal fillers, fat or botulinum toxin, as well as any minimally
             invasive/invasive medical device for skin treatment, in the study treatment areas,
             within the past 6 months (i.e., dermabrasion, laser, RF devices)

          -  Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment

          -  Active, chronic, or recurrent infection

          -  History of compromised immune system or currently being treated with immunosuppressive
             agents

          -  History of sensitivity to analgesic agents, AquaphorÂ®, topical or local anesthetics
             (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or
             epinephrine

          -  Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior
             to treatment

          -  Treatment with aspirin or other blood thinning agents within 14 days prior to
             treatment

          -  History or presence of any clinically significant bleeding disorder

          -  Any issue that, at the discretion of the Investigator, would interfere with assessment
             of safety or efficacy or compromise the subject's ability to participate in the study

          -  Treatment with an investigational device or agent within 30 days before treatment or
             during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laser and Skin Surgery Center of Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AboutSkin Research, LLC</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey Langhorst</last_name>
      <phone>303-756-7546</phone>
      <email>research@aboutskinderm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Dermatology &amp; Laser Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laser and Skin Surgery of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Moreno</last_name>
      <phone>212-686-7306</phone>
      <email>research@laserskinsurgery.com</email>
    </contact>
    <investigator>
      <last_name>Roy Geronemus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Office of Brian Biesman, M.D.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Casey Martin</last_name>
      <phone>214-823-1978</phone>
      <email>Casey.Martin@dpsi.org</email>
    </contact>
    <investigator>
      <last_name>Jay Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>facial wrinkles</keyword>
  <keyword>skin laxity</keyword>
  <keyword>sagging skin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

